Fig. 5.
Cisplatin and intratumoral injection of CRT/E7-VV elicits a systemic anti-tumor effect and therapeutic immune response. a Schematic diagram of cisplatin and VV treatments. Groups of C57BL/6 mice (five per group) were s.c. challenged with 1 × 105TC-1 tumor cells per mouse on both flanks. TC-1 tumor-bearing mice were treated with cisplatin and/or CRT/E7-VV as indicated in the time line. Vaccinia virus was injected via intraperitoneal or intratumoral injection (left flank tumor) in the amount of 3 × 106 PFU/mouse. b Line graphs depicting the tumor volume in TC-1 tumors. Upper panel is left flank tumor volume. Lower panel is right flank tumor volume. Points, mean; bars, SE. c Tumor-infiltrating lymphocytes (collected from the right flank tumor mass) were stained with PE-conjugated HPV E7 tetramer reagent and FITC-conjugated CD8+ cells. Upper panel is representative flow cytometry analysis. Lower panel is a bar graph representing the percentage of E7-specific CD8+ T cells among all CD8+ T cells of tumor mass. Data shown are representative of two experiments performed. Columns, mean; bars, SE (*p < 0.05)